A number of scientists have wondered if aluminum, a vaccine additive that has been used for decades, had a role in allergies and asthma in children.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced positive Phase 1 data from its Phase 1/2 trial of the first of its enveloped virus-like particle (eVLP) COVID-19 vaccine candidates, VBI-2902a, in healthy adults age 18-54 years of age. The 5µg dose of VBI-2902a, which expresses an optimized SARS-CoV-2 spike antigen and is adjuvanted with aluminum phosphate, was generally well-tolerated and elicited potent immune responses significantly higher than those seen in human convalescent sera. The data establish a robust human proof-of-concept, at a low dose without the use of a next-generation adjuvant, demonstrating the potency of the eVLP particulate delivery platform against COVID-19.
The opening of the four-story facility comes on the heels of GSK’s announcement that it plans to spend an additional $37 million to support the production of medicines for respiratory illnesses at the site. The Montrose facility is focused on the production of salbutamol, the API in Ventolin, a treatment for asthma and chronic obstructive pulmonary disease.
Enforcement Report - Week of July 5, 2017
The decision, by U.S. District Judge Amy Berman Jackson, said the proposed $48 billion deal violated federal antitrust law because it would create an unacceptable reduction in the number of companies able to serve large multistate employers that insure their workers.